Johnson & Johnson JNJ

271.22 0.54 0.20% as of 25 Sep
Market cap
$652.8B
P/E
31.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Johnson & Johnson (JNJ) Debt to equity

Johnson & Johnson's debt to equity at the end of the quarter to 30 June 2026 was 0.4×, down 0.0× from fiscal 2025 (0.5×). Over the past ten years it has ranged from 0.2× (fiscal 2015) to 0.5× (fiscal 2020); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Annual

Period Debt to equity Change
FY2025 0.5× 12.81%
FY2024 0.4× 13.93%
FY2023 0.4× 7.48%
FY2022 0.4× (13.58%)
FY2021 0.4× (21.45%)
FY2020 0.5× 15.76%
FY2019 0.4× (3.84%)
FY2018 0.5× (9.14%)
FY2017 0.5× 59.99%
FY2016 0.3× 76.37%

Quarterly

Period Debt to equity Change
Jun 2026 0.4× (4.91%)
Mar 2026 0.5× (4.43%)
Dec 2025 0.5× (2.72%)
Sep 2025 0.5× (0.58%)
42 more quarters

Against its own ten years

Low 0.2× High 0.5×
Ten-year median 0.4×
Current reading's percentile 82

Debt to equity against peers

Company Debt to equity
ABBV AbbVie Inc. compare −12.0×
JNJ Johnson & Johnson 0.4×
AZN AstraZeneca PLC compare 0.6×
PFE Pfizer Inc. compare 0.7×
NVS Novartis AG compare 1.1×
MRK Merck & Co., Inc. compare 1.2×
LLY Eli Lilly and Company compare 1.6×
GILD Gilead Sciences, Inc. compare 2.2×
AMGN Amgen Inc. compare 4.9×
Drug Manufacturers General industry median 0.6×
Healthcare sector median 0.0×
Market median 0.2×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on JNJ